Company Jaguar Health, Inc.

Equities

JAGX

US47010C8055

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2024 am IST			5-day change	1st Jan Change
3.69 ^USD	+1.93%		-5.99%	-59.38%

30/05	Top Premarket Gainers	MT
29/05	Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences	MT

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Number of employees: 49

USD in Million	2022	Weight	2023	Weight	Delta
Human Health 98.2 %	12	98.2 %	10	98.2 %	-18.34%
Animal Health 1.8 %	0	1.8 %	0	1.8 %	-19.53%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	12	100.0 %	10	100.0 %	-18.36%

Managers	Title	Age	Since
Lisa Conte FOU	Founder	65	06/13/06
Carol Lizak DFI	Director of Finance/CFO	60	01/19/01
Pravin Ramsewak Chaturvedi CTO	Chief Tech/Sci/R&D Officer	60	01/17/01
Jonathan Wolin CMP	Compliance Officer	62	01/18/01
Darlene P. Horton CTO	Chief Tech/Sci/R&D Officer	62	01/21/01
Peter C. Hodge IRC	Investor Relations Contact	-	-
Karen Brunke PRN	Corporate Officer/Principal	72	09/21/09
Ian Wendt PRN	Corporate Officer/Principal	-	-
David Sesin PRN	Corporate Officer/Principal	-	-
Steven King PRN	Corporate Officer/Principal	66	01/04/01

Members of the board	Title	Age	Since
Lisa Conte FOU	Founder	65	06/13/06
James Bochnowski CHM	Chairman	80	01/14/01
John Micek BRD	Director/Board Member	71	01/16/01
Jonathan Siegel BRD	Director/Board Member	50	29/18/29
Anula Kusum Jayasuriya BRD	Director/Board Member	67	01/22/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,282,926	4,528,234 ( 85.71 %)	0	85.71 %

Name	Equities	%	Valuation
Fife Trading, Inc. 8.052 %	393,700	8.052 %	2 M $
GEN ILAC VE SAGLIK URUNLERI SANAYI VE TICARET ANONIM SIRKETI 5.682 %	277,783	5.682 %	1 M $
BlackRock Institutional Trust Co. NA 0.8849 %	43,264	0.8849 %	182 574 $
Fredrick Waid 0.6441 %	31,493	0.6441 %	132 900 $
Commonwealth Equity Services LLC 0.3065 %	14,986	0.3065 %	63 241 $
Jane Street Group LLC 0.2722 %	13,308	0.2722 %	56 160 $
XTX Topco Ltd. 0.1536 %	7,511	0.1536 %	31 696 $
BofA Securities, Inc. 0.0826 %	4,040	0.0826 %	17 049 $
Vanguard Group, Inc. (Subfiler) 0.0656 %	3,206	0.0656 %	13 529 $
G1 Execution Services LLC 0.0536 %	2,622	0.0536 %	11 065 $

Jaguar Health, Inc.

200 Pine Street Suite 400

94104, San Francisco

http://www.jaguar.health

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.69 USD

Average target price

36 USD

Spread / Average Target

+875.61%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
JAGUAR HEALTH, INC.	-59.38%	1.95Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.93%	12TCr
REGENERON PHARMACEUTICALS, INC.	+17.01%	11TCr
BIONTECH SE	-7.23%	2.36TCr
ARGENX SE	+2.88%	2.26TCr
GENMAB A/S	-14.92%	1.73TCr
BEIGENE, LTD.	-6.79%	1.76TCr
WUXI APPTEC CO., LTD.	-37.63%	1.76TCr
NEUROCRINE BIOSCIENCES, INC.	+2.17%	1.35TCr
SAREPTA THERAPEUTICS, INC.	+24.42%	1.13TCr

Bio Therapeutic Drugs